W. Bakker

发表

LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN

E. P. Krenning, W. H. Bakker, E. Krenning, 1989, The Lancet.

Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.

T. Visser, B. Bernard, E. Rolleman, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.

E. Krenning, D. Kwekkeboom, W. D. de Herder, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy

B. Bernard, E. Krenning, M. Jong, 2000 .

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

T. Visser, R. Valkema, E. Krenning, 2001, European Journal of Nuclear Medicine.

[177Lu‐DOTA0,Tyr3]octreotate for somatostatin receptor‐targeted radionuclide therapy

B. Bernard, E. Krenning, W. Breeman, 2001, International journal of cancer.

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

R. Valkema, E. Krenning, M. Jong, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.

R. Valkema, B. Bernard, E. Krenning, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma

E. Krenning, J. Erion, M. de Jong, 2000, European Journal of Nuclear Medicine.

Somatostatin-receptor imaging in the localization of endocrine tumors.

E. Krenning, S. Lamberts, J. Reubi, 1990, The New England journal of medicine.

99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo.

T. Visser, B. Bernard, E. Krenning, 1998, Nuclear medicine and biology.

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Marion de Jong, Mark Konijnenberg, F. Forrer, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.

L. Kvols, R. Valkema, E. Krenning, 2002, Seminars in nuclear medicine.

Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog

E. Krenning, S. Lamberts, J. Reubi, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.

E. Krenning, S. Lamberts, J. Reubi, 1990, Metabolism: clinical and experimental.

Volume depletion and natriuresis in patients with a ruptured intracranial aneurysm

E. Wijdicks, J. van Gijn, M. Vermeulen, 1985, Annals of neurology.

Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage.

G. Murray, E. Wijdicks, J. van Gijn, 1989, Stroke.

Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy

T. Visser, E. Krenning, M. Jong, 1996, European Journal of Nuclear Medicine.

The role of radioactive somatostatin and its analogues in the control of tumor growth.

R. Valkema, E. Krenning, M. Jong, 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.

R. Valkema, E. Krenning, W. Breeman, 1999, Italian journal of gastroenterology and hepatology.

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

T. Visser, B. Bernard, E. Krenning, 1997, European Journal of Nuclear Medicine.

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.

E. Krenning, D. Kwekkeboom, H. Mäcke, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.

H. Bruining, E. Krenning, S. Lamberts, 1990, The Journal of clinical endocrinology and metabolism.

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

E. Krenning, M. O. Aken, M. Essen, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

E. P. Krenning, W. H. Bakker, A. E. M. Reijs, 1993, European Journal of Nuclear Medicine.

A Case History

H., M., W. Breeman, 2006 .

in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors

L. Kvols, R. Valkema, E. Krenning, 2006 .

Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy

T. Visser, B. Bernard, E. Rolleman, 1995, European Journal of Nuclear Medicine.

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

T. Visser, E. Krenning, M. Jong, 2004, European Journal of Nuclear Medicine.

In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man.

T. Visser, E. Krenning, S. Lamberts, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer.

E. Krenning, S. Lamberts, T. Splinter, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin analogue scintigraphy in carcinoid tumours

E. Krenning, S. Lamberts, D. Kwekkeboom, 1993, European Journal of Nuclear Medicine.

Somatostatin analogue scintigraphy of malignant lymphomas

E. Krenning, B. Löwenberg, W. Bakker, 1993, British journal of haematology.

Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.

J. Klijn, T. Visser, E. Krenning, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.

T. Visser, E. Krenning, M. Jong, 1991, Life sciences.

The detection of virally induced tumors by 131I- and 125I-labeled syngeneic monoclonal antibodies

W. Breeman, W. Bakker, N. J. Both, 2004, Cancer Immunology, Immunotherapy.

Comparison of uptake of99mTc-MIBI,99mTc-tetrofosmin and99mTc-012 into human breast cancer cell lines

T. Visser, B. Bernard, E. Krenning, 1996, European Journal of Nuclear Medicine.

Relationships between the lung-heart ratio assessed from post-exercise thallium-201 myocardial tomograms, myocardial ischemia and the extent of coronary artery disease

J. Reiber, A. Reijs, B. Ilmer, 2006, The International Journal of Cardiac Imaging.

Radiopharmaceuticals for scintigraphy of somatostatin receptor-positive tumors

W. Bakker, 1992 .

Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas

J. Marienhagen, W. Breeman, W. Bakker, 1991, European Journal of Nuclear Medicine.

Site-specific intracoronary heparin delivery in humans after balloon angioplasty. A radioisotopic assessment of regional pharmacokinetics.

P. Serruys, M. Kutryk, J. Roelandt, 1997, Circulation.

Endocrine Gastroenteropancreatic Tumors

E. Krenning, D. Kwekkeboom, B. Kam, 2005 .

Permeability of human isolated airways increases after hydrogen peroxide and poly-L-arginine.

J. D. de Jongste, P. Saxena, W. Bakker, 1996, American journal of respiratory and critical care medicine.

Studies on radiolabeled somatostatin analogues in rats and in patients.

T. Visser, E. Krenning, W. Breeman, 1996, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.

T. Visser, B. Bernard, E. Rolleman, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.

T. Visser, E. Krenning, S. Lamberts, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

T. Visser, B. Bernard, E. Krenning, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy

T. Visser, B. Bernard, E. Krenning, 1998, International journal of cancer.

Tumour uptake of the radiolabelled somatostatin analogue [DOTA0,TYR3]octreotide is dependent on the peptide amount

T. Visser, B. Bernard, E. Krenning, 1999, European Journal of Nuclear Medicine.

Radiotherapy with a Radiolabeled Somatostatin Analogue, [lllIn-DTPA-~-Phel] -0ctreo tide A Case History

H., M., E. Krenning, 2006 .

Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors.

L. Kvols, R. Valkema, E. Krenning, 2002 .

OctreoTherTM: Ongoing Early Clinical Development of a Somatostatin-Receptor-Targeted Radionuclide Antineoplastic Therapy

L. Kvols, R. Valkema, E. Krenning, 2000, Digestion.

Tumor dosimetry based on PET Y-86-DOTA-Tyr3-octreotide (SMT487) and CT-scan predicts tumor response to Y-90-SMT487 (OctreoTher (TM)) therapy.

L. Kvols, S. Walrand, R. Valkema, 2000 .

Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy

T. Visser, E. Krenning, W. Breeman, 2000, Nuclear medicine communications.

Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method

J. Verweij, E. Krenning, W. Loos, 2006, Anti-Cancer Drugs.

Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.

E. Krenning, W. Breeman, D. Kwekkeboom, 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium

E. Krenning, M. Jong, W. Breeman, 2020 .

Somatostatin analogue scintigraphy in granulomatous diseases

E. Krenning, J. Reubi, D. Kwekkeboom, 1994, European Journal of Nuclear Medicine.

Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide

T. Visser, E. Krenning, M. Jong, 1993, European Journal of Nuclear Medicine.

Radioiodinated SomatostatinAnalog Scintigraphy in Small-CellLung Cancer

E. Krenning, S. Lamberts, T. Splinter, 1991 .

Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study

L. Kvols, R. Valkema, E. Krenning, 2001 .

The effect of iso-oncotic plasma substitutes: gelatine, dextran 40 (50 g/l) and the effect of Ringer's lactate on the plasma volume in healthy subjects.

A. Trouwborst, W. Bakker, W. G. van den Broek, 1989, Acta anaesthesiologica Belgica.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

E. P. Krenning, W. H. Bakker, E. Krenning, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Discrepancies between iodine and technetium thyroid scintigraphy.

G. Hennemann, W. Bakker, J. Barth, 1978, JAMA.

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.

T. Visser, E. Krenning, S. Lamberts, 1991, Life sciences.

In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P.

T. Visser, E. Krenning, S. Lamberts, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Marion de Jong, Raffaella Barone, L. Kvols, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Pulmonary 99mTc-human serum albumin clearance and effects of surfactant replacement after lung lavage in rabbits.

D. Gommers, S. Verbrugge, P. Wollmer, 1996, Critical care medicine.

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

E. Krenning, J. Erion, M. de Jong, 2001, European Journal of Nuclear Medicine.

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.

R. Valkema, E. Krenning, M. Stridsberg, 2002, Seminars in nuclear medicine.

Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.

T. Visser, E. Krenning, S. Lamberts, 1994, Seminars in oncology.

Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.

E. Krenning, D. Kwekkeboom, J. Teunissen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Plasma lysozyme level and reticuloendothelial system function in human liver disease.

J. Lindemans, J. Wilson, W. Bakker, 1981, Clinica chimica acta; international journal of clinical chemistry.

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

E P Krenning, J C Reubi, T. Visser, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Site-specific intravascular administration of drugs: history of a method applicable in humans.

P. Serruys, J. Roelandt, E. Krenning, 1997, Catheterization and cardiovascular diagnosis.

Efficacy of Percutaneous Intramyocardial Injections Using a Nonfluoroscopic 3-D Mapping Based Catheter System

P. Serruys, E. Krenning, W. J. van der Giessen, 2002, Cardiovascular Drugs and Therapy.

772-2 Local Intracoronary Delivery of Heparin and of a Somatostatin Analogue (Octreotide) Following Angioplasty in Man: Evaluation of Efficacy of Delivery by Radio-Isotopic Technique

P. Serruys, E. Krenning, E. Camenzind, 1995 .

Clinical validation of fully automated computation of ejection fraction from gated equilibrium blood-pool scintigrams.

J. J. Gerbrands, W. Wijns, W H Bakker, 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Site-Specific Intracoronary Delivery of Octreotide in Humans: A Pharmacokinetic Study to Determine Dose-Efficacy in Restenosis Prevention

P. Serruys, A. Righetti, J. Roelandt, 2004, Journal of cardiovascular pharmacology.

Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐Octreotide

T. Visser, E. Krenning, M. Jong, 1994 .

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.

E P Krenning, E. Krenning, J. Erion, 2001, European journal of nuclear medicine.

Radiolabeling DOTA-Peptides with 90Y and 177Lu to a High Specific Activity

E. Krenning, W. Breeman, W. Bakker, 2016 .

Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?

E. P. Krenning, W. H. Bakker, E. Krenning, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Peptide receptor scintigraphy (PRS) with In-111-DOTANOC and peptide receptor radionuclide therapy (PRRT) with Lu-177-DOTANOC

R. Valkema, E. Krenning, M. Jong, 2007 .

Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Raffaella Barone, Stanislas Pauwels, L. Kvols, 2006, Seminars in nuclear medicine.

Clearance of 99mTc-DTPA and experimentally increased alveolar surfactant content.

P. Wollmer, B. Lachmann, W. Bakker, 1992, Journal of applied physiology.

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.

E P Krenning, T. Visser, B. Bernard, 1998, Cancer research.

Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.

E P Krenning, T. Visser, B. Bernard, 1998, Nuclear medicine communications.

A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide

T. Visser, E. Krenning, M. Jong, 1994, European Journal of Nuclear Medicine.

Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors

E. Krenning, S. Lamberts, J. Reubi, 1993, World Journal of Surgery.

LEFT VENTRICULAR AND BACKGROUND COUNT DENSITIES AVERAGED OVER ALL STUDIES IN THE THREE DIFFERENT GROUPS LEAP coll

J. J. Gerbrands, M. Simoons, W. Wijns, 2006 .

Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats.

T. Visser, B. Bernard, E. Rolleman, 1997, Nuclear medicine and biology.

Radiation protection in nuclear medicine and pathology: K.E. Goldstone, P.C. Jackson, M.J. Myers, and A.E. Simpson (Editors) The Institute of Physical Sciences in Medicine 1991, Report No. 63. ISBN 0 904181 62 6

W. Breeman, W. Bakker, 1992 .

Phase I Study of Peptide Receptor Radionuclide Therapy With (lllIn-DTPA~

R. Valkema, E. Krenning, M. Jong, 2002 .

[DOTA,Tyr3]octreotate, labeled with 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors

B. Bernard, E. Krenning, M. Jong, 2000 .

ST-Vector Orientation and Location of Myocardial Perfusion Defects during Exercise

M. Simoons, R. Vinke, W. Bakker, 1978, Nuklearmedizin.

Radiation dosimetry for indium-111-pentetreotide.

K. Endo, M. Stabin, P. Kooij, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of uptake of 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 into human breast cancer cell lines.

T. Visser, B. Bernard, E. Krenning, 1996, European Journal of Nuclear Medicine.

mplementation and performance of a general purpose graphics rocessing unit in hyperspectral image analysis

Harald van der Werff, Wim H. Bakker, W. Bakker, 2013 .

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

T. Visser, E. Krenning, M. Jong, 1993, European Journal of Nuclear Medicine.

Orthotolidine test not to be used for detection of blood in gastric juice.

W. Bakker, M. van Blankenstein, H. V. VAN ESSEN, 1985, Clinica chimica acta; international journal of clinical chemistry.